Is INVO BioScience, Inc. overvalued or undervalued?

As of 15 May 2023, the valuation grade for INVO BioScience, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its significant losses, as evidenced by a Price to Book Value of 0.13, an EV to EBIT of -0.75, and an EV to EBITDA of -0.83. In comparison to peers, NanoVibronix, Inc. has a more pronounced EV to EBITDA of -0.2892, while Nuwellis, Inc. shows an EV to EBIT of -0.2109, suggesting that INVO BioScience is lagging behind its competitors in terms of valuation metrics.
Furthermore, the company's stock performance has been dismal, with a year-to-date return of -97.01%, starkly contrasting with the S&P 500's positive return of 12.22% during the same period. This dramatic underperformance reinforces the notion that INVO BioScience is overvalued in its current state.